Discovering Anti-Cancer Drugs via Computational Methods
Author:
Publisher
Frontiers Media SA
Subject
Pharmacology (medical),Pharmacology
Reference134 articles.
1. Entrectinib: first global approval;Al-Salama;Drugs,2019
2. Apalutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer;Al-Salama;Drugs,2019
3. Structure Based Drug Design of Angiotensin-I Converting Enzyme Inhibitors;Anthony;Curr. Med. Chem.,2012
4. Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial;Atkins;Lancet Oncol.,2018
5. Duvelisib: First global approval;Blair;Drugs,2018
Cited by 144 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Novel Computational Methods for Cancer Drug Design;Current Medicinal Chemistry;2024-02
2. Anticancer Drug Discovery Based on Natural Products: From Computational Approaches to Clinical Studies;Biomedicines;2024-01-16
3. In Silico Therapeutic Study: The Next Frontier in the Fight against SARS-CoV-2 and Its Variants;Drugs and Drug Candidates;2024-01-05
4. Computational exploration of allosteric inhibitors targeting CDK4/CDK6 proteins: a promising approach for multi-target drug development;Journal of Biomolecular Structure and Dynamics;2024-01-04
5. A comprehensive review on anticancer evaluation techniques;Bioorganic Chemistry;2024-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3